Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients

Kai Che Wei, Chenglen Sy, Shang Yin Wu, Tzu Jung Chuang, Wei Chun Huang, Ping Chin Lai

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Rituximab is associated with a higher incidence of Pneumocystis jirovecii pneumonia infection. Pneumocystis prophylaxis is advised in many immunocompromised populations treated with rituximab. However, the beneficial effect of pneumocystis prophylaxis in HIV-uninfected, rituximab-treated non-Hodgkin lymphoma (NHL) patients has not been assessed. Thus, we conducted this retrospective study to explore pneumocystis infection in HIV-uninfected NHL patients who received at least three courses of chemotherapy without haematopoietic stem cell transplantation using the Taiwan National Health Insurance Research Database. Patients who had rituximab-based chemotherapy were included in the experimental (rituximab) group, while the rest of the patients who did not receive any rituximab-based chemotherapy throughout the study period formed the control group. The prevalence rate of pneumocystis infection in the rituximab group (N = 7,554) was significantly higher than that in the control group (N = 4,604) (2.95% vs. 1.32%). The onset of pneumocystis infection occurred between 6 and 16 weeks after chemotherapy. Patients who had pneumocystis prophylaxis, whether or not they had a pneumocystis infection later in their treatment course, had significantly better first-year survival rates (73% vs. 38%). Regular pneumocystis prophylaxis should be considered in this group of patients.

Original languageEnglish
Article number8321
JournalScientific reports
Volume8
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Pneumocystis carinii
Pneumocystis Pneumonia
Non-Hodgkin's Lymphoma
Pneumocystis
Pneumocystis Infections
HIV
Drug Therapy
Control Groups
Hematopoietic Stem Cell Transplantation
National Health Programs
Rituximab
Taiwan
Survival Rate
Retrospective Studies
Databases
Incidence
Infection
Research
Population

All Science Journal Classification (ASJC) codes

  • General

Cite this

Wei, Kai Che ; Sy, Chenglen ; Wu, Shang Yin ; Chuang, Tzu Jung ; Huang, Wei Chun ; Lai, Ping Chin. / Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients. In: Scientific reports. 2018 ; Vol. 8, No. 1.
@article{69c894a9e0744d70a72d0e62deca62f8,
title = "Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients",
abstract = "Rituximab is associated with a higher incidence of Pneumocystis jirovecii pneumonia infection. Pneumocystis prophylaxis is advised in many immunocompromised populations treated with rituximab. However, the beneficial effect of pneumocystis prophylaxis in HIV-uninfected, rituximab-treated non-Hodgkin lymphoma (NHL) patients has not been assessed. Thus, we conducted this retrospective study to explore pneumocystis infection in HIV-uninfected NHL patients who received at least three courses of chemotherapy without haematopoietic stem cell transplantation using the Taiwan National Health Insurance Research Database. Patients who had rituximab-based chemotherapy were included in the experimental (rituximab) group, while the rest of the patients who did not receive any rituximab-based chemotherapy throughout the study period formed the control group. The prevalence rate of pneumocystis infection in the rituximab group (N = 7,554) was significantly higher than that in the control group (N = 4,604) (2.95{\%} vs. 1.32{\%}). The onset of pneumocystis infection occurred between 6 and 16 weeks after chemotherapy. Patients who had pneumocystis prophylaxis, whether or not they had a pneumocystis infection later in their treatment course, had significantly better first-year survival rates (73{\%} vs. 38{\%}). Regular pneumocystis prophylaxis should be considered in this group of patients.",
author = "Wei, {Kai Che} and Chenglen Sy and Wu, {Shang Yin} and Chuang, {Tzu Jung} and Huang, {Wei Chun} and Lai, {Ping Chin}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-26743-4",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients. / Wei, Kai Che; Sy, Chenglen; Wu, Shang Yin; Chuang, Tzu Jung; Huang, Wei Chun; Lai, Ping Chin.

In: Scientific reports, Vol. 8, No. 1, 8321, 01.12.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients

AU - Wei, Kai Che

AU - Sy, Chenglen

AU - Wu, Shang Yin

AU - Chuang, Tzu Jung

AU - Huang, Wei Chun

AU - Lai, Ping Chin

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Rituximab is associated with a higher incidence of Pneumocystis jirovecii pneumonia infection. Pneumocystis prophylaxis is advised in many immunocompromised populations treated with rituximab. However, the beneficial effect of pneumocystis prophylaxis in HIV-uninfected, rituximab-treated non-Hodgkin lymphoma (NHL) patients has not been assessed. Thus, we conducted this retrospective study to explore pneumocystis infection in HIV-uninfected NHL patients who received at least three courses of chemotherapy without haematopoietic stem cell transplantation using the Taiwan National Health Insurance Research Database. Patients who had rituximab-based chemotherapy were included in the experimental (rituximab) group, while the rest of the patients who did not receive any rituximab-based chemotherapy throughout the study period formed the control group. The prevalence rate of pneumocystis infection in the rituximab group (N = 7,554) was significantly higher than that in the control group (N = 4,604) (2.95% vs. 1.32%). The onset of pneumocystis infection occurred between 6 and 16 weeks after chemotherapy. Patients who had pneumocystis prophylaxis, whether or not they had a pneumocystis infection later in their treatment course, had significantly better first-year survival rates (73% vs. 38%). Regular pneumocystis prophylaxis should be considered in this group of patients.

AB - Rituximab is associated with a higher incidence of Pneumocystis jirovecii pneumonia infection. Pneumocystis prophylaxis is advised in many immunocompromised populations treated with rituximab. However, the beneficial effect of pneumocystis prophylaxis in HIV-uninfected, rituximab-treated non-Hodgkin lymphoma (NHL) patients has not been assessed. Thus, we conducted this retrospective study to explore pneumocystis infection in HIV-uninfected NHL patients who received at least three courses of chemotherapy without haematopoietic stem cell transplantation using the Taiwan National Health Insurance Research Database. Patients who had rituximab-based chemotherapy were included in the experimental (rituximab) group, while the rest of the patients who did not receive any rituximab-based chemotherapy throughout the study period formed the control group. The prevalence rate of pneumocystis infection in the rituximab group (N = 7,554) was significantly higher than that in the control group (N = 4,604) (2.95% vs. 1.32%). The onset of pneumocystis infection occurred between 6 and 16 weeks after chemotherapy. Patients who had pneumocystis prophylaxis, whether or not they had a pneumocystis infection later in their treatment course, had significantly better first-year survival rates (73% vs. 38%). Regular pneumocystis prophylaxis should be considered in this group of patients.

UR - http://www.scopus.com/inward/record.url?scp=85047859804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047859804&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-26743-4

DO - 10.1038/s41598-018-26743-4

M3 - Article

C2 - 29844519

AN - SCOPUS:85047859804

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 8321

ER -